<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">Secondary malignancies</z:e>, particularly <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), are serious events following high dose therapy with autologous stem cell support </plain></SENT>
<SENT sid="1" pm="."><plain>We observed a higher frequency of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary malignancies</z:e> in patients with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) than in patients with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) undergoing high dose therapy with the same non-TBI conditioning regimen </plain></SENT>
<SENT sid="2" pm="."><plain>Three hundred patients with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) were treated with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="3423">carmustine</z:chebi> and <z:chebi fb="0" ids="4911">etoposide</z:chebi> and autologous stem cell support from 1986 through 1994 </plain></SENT>
<SENT sid="3" pm="."><plain>Median follow up of survivors is 3.9 years </plain></SENT>
<SENT sid="4" pm="."><plain>Five-year survival is 51% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> and 48% for NHL </plain></SENT>
<SENT sid="5" pm="."><plain>Eleven patients developed <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e> (9/150 treated for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> vs. 2/150 treated for NHL) a median of 2.4 years from transplantation and 5.2 years from initial diagnosis </plain></SENT>
<SENT sid="6" pm="."><plain>Six patients had <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> or <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and 5 had <z:hpo ids='HP_0002665'>lymphomas</z:hpo> or <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Actuarial risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> at five years for patients transplanted for non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is 3% (95% CI 0.6-9.6%) </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> patients had significantly different pretreatment characteristics than patients with NHL </plain></SENT>
<SENT sid="9" pm="."><plain>A Cox model showed that greater number of prior relapses and prior radiation therapy were significant risk factors for the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>These data suggest that CBV is associated with a lower risk of <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> than TBI containing regimens and that much of the risk is associated with the pre-transplantation therapy </plain></SENT>
<SENT sid="11" pm="."><plain>The use of autotransplantation early in the course of therapy for relapsed <z:hpo ids='HP_0002665'>lymphoma</z:hpo> might prevent some cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>